Several clinicopathologic features of HER2-positive breast cancer patients were found to be associated with response to neoadjuvant therapy in a new study.
The trial examined HER2-positive breast cancer in patients with tumors smaller than 1cm; it is one of only a few to assess treatments in tumors this small.
A new study found a low rate of cancer recurrence at the nipple-areola complex (NAC) in patients with breast cancer who underwent nipple-sparing mastectomy (NSM).
A new combo may benefit patients with HER-2 positive metastatic breast cancer, according to a new study.
A new analysis looked at how dose interruptions or reductions of ado-trastuzumab emtansine in the treatment of advanced HER2-positive breast cancer impacted long-term survival outcomes.
Researchers looked at the characteristics of breast cancer found in patients under 40 years old.
A phase III trial tested trastuzumab emtansine (T-DM1) with or without pertuzumab in patients with HER2-positive metastatic breast cancer.
Researchers compared invasive disease-free survival rates in patients with breast cancer who took nanoparticle albumin-bound (NAB)-paclitaxel compared with those who took solvent-based (sb)-paclitaxel.
A trial presented at ASCO 2019 found HER2 heterogenity can impact response rates to some treatments in HER2-positive breast cancer patients.
Novel research suggests that using a nano-molecularly imprinted polymer may offer a unique and effective way to treat HER2+ breast cancer.